Pulmatrix earnings release, May 15, 2026

Pulmatrix, Inc. (PULM) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Pulmatrix

Announces First Quarter 2026 Financial Results

Announced merger agreement with Eos SENOLYTIX in March

Closed private placement of preferred stock

Framingham,

Mass., May 15, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update.

Peter

Ludlum, Interim Chief Executive Officer of Pulmatrix, commented,

“Our focus in the first quarter was on our work to secure a strategic transaction for our company and our shareholders. We are pleased to report that on March 26 th we announced entering into a merger agreement with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using its proprietary

MitoXcel™ platform. We also secured aggregate gross proceeds of $1 million from a private placement of preferred stock from an affiliate of Eos. Separate from the preferred stock, our common stockholders will receive approximately 6% interest in the new combined company without dilution from the preferred stock.”

Proposed

Merger with Eos SENOLYTIX

As previously reported, on March 26, 2026, the Company entered into an agreement (the “Merger Agreement”) and plan of merger

(the “Merger”) with Eos SENOLYTIX, Inc. (“Eos”). The proposed Merger is anticipated to close in the third quarter of 2026, subject to customary closing conditions. If the proposed Merger is completed, the business of Eos will continue as the business of the combined company.

In connection with the entry into the Merger Agreement, on March 26, 2026, the Company announced that it entered into a securities purchase agreement with an affiliate of Eos for the issuance and sale in a private placement of its newly designated Series B Convertible Preferred

Stock, raising aggregate gross proceeds of $1.0 million.

Additional information about the Merger Agreement was previously disclosed on a Current Report on Form 8-K filed with the SEC on March 27, 2026.

Pulmatrix

Seeks to Out-license or Monetize its Clinical Assets iSPERSE™

Technology

PUR1900

PUR3100

PUR1800

First

Quarter 2026 Financial Results

Research and development expenses were less than $0.1 million for both the three months ended March 31, 2026, and 2025. All clinical development is currently on hold while the Company works to license or monetize our clinical assets.

General and administrative expenses decreased approximately $0.5 million to $1.3 million for the three months ended March 31, 2026, compared to $1.8 million for the three months ended March 31, 2025. The decrease was primarily due to higher costs incurred in the three months ended March 31, 2025, related to the preparation and filing of a registration statement on Form S-4 and amendments thereto with the SEC.

The

Company’s total cash and cash equivalents balance as of

March 31, 2026, was $3.3 million, compared to $4.1 million as of December 31, 2025. The Company’s unaudited financial statements were prepared assuming that the Company will continue as a going concern within one year after the date such financial statements are issued. The Company anticipates that its cash position, based on current operational efficiencies and prioritization of spending, is sufficient to fund its operations at least through the anticipated closing of the proposed Merger with Eos.

PULMATRIX,

INC.

Consolidated

Balance Sheets

(in thousands, except share and per share data)

PULMATRIX,

INC.

Consolidated

Statements of Operations

(in thousands, except share and per share data)

(unaudited)

About

Pulmatrix, Inc.

Pulmatrix is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis

(“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on the Company’s inhaled product candidates please visit: https://www.pulmatrix.com/pipeline.html.

About

Eos SENOLYTIX, Inc.

Eos

SENOLYTIX is a biotechnology company focused on developing first-in-class gerotherapeutic peptide medicines that target the underlying biological mechanisms of aging. Eos’s lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides, have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both via a single, aging-specific target, the mitochondrial membrane potential (MMP), also called the “Δψm”. These two mechanisms include (1) the return of the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype, and (2) the profound elimination of senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects. Extensive preclinical studies suggest the MitoXcel™ platform may be a broad gerotherapeutic that improves... (truncated)g animals. By targeting fundamental processes driving aging and aging-related diseases, Eos SENOLYTIX is pursuing a unique therapeutic opportunity to intervene in the aging process in ways that were once thought impossible. Eos SENOLYTIX is headquartered in Houston, Texas and operates within the broader SENOTHERAPEUTIX /

GEROTHERAPEUTIX group of longevity companies, which focuses on developing therapeutics targeting fundamental drivers of aging to improve healthspan and lifespan. For more information, visit https://www.eossenolytix.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — (unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating expenses:Research and development319
Operating expenses:General and administrative1,2891,828
Operating expenses:Total operating expenses1,2921,847
Operating expenses:Loss from operations-1,292-1,847
Other income (expense):Interest income1253
Other income (expense):Fair value adjustment of warrants66
Other income (expense):Other income (expense), net108-80
Other income (expense):Total other income (expense), net12039
Other income (expense):Net loss-1,172-1,808
Other income (expense):Net loss per share attributable to common stockholders – basic and diluted-0.32-0.5
Other income (expense):Weighted average common shares outstanding – basic and diluted3,652,2853,652,285

Balance Sheet

March 31, 2026 — (in thousands, except share and per share data)

March 31, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents3,3244,088
Current assets:Restricted cash700
Current assets:Prepaid expenses and other current assets46541
Current assets:Total current assets4,4894,129
Current assets:Long-term restricted cash710
Current assets:Total assets4,4964,139
Current liabilities:Accounts payable651272
Current liabilities:Accrued expenses and other current liabilities25457
Current liabilities:Total current liabilities905329
Current liabilities:Total liabilities905329
Stockholders’ equity:Preferred Stock, $0.0001 par value — 500,000 shares authorized; 1,100 shares designated as Series B Convertible Preferred Stock; no shares issued and outstanding at March 31, 2026, and December 31, 2025; 1,000 shares of Series B Convertible Preferred Stock issuable at March 31, 2026950
Stockholders’ equity:Additional paid-in capital306,131306,128
Stockholders’ equity:Accumulated deficit-303,490-302,318
Stockholders’ equity:Total stockholders’ equity3,5913,810
Stockholders’ equity:Total liabilities and stockholders’ equity4,4964,139
Full release

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements include, but are not limited to, statements of historical fact and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,”

“could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,”

“is confident that,” “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management and include, but are not limited to, the use of proceeds from the private placement and conversion of the Series B Preferred Stock. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the consummation of any other potential reverse merger transaction in the future, among others; the Company’s ability to divest its clinical assets on terms favorable to the Company, or at all, the Company’s ability to maintain compliance with the listing standards of the Nasdaq Capital Market; the Company’s ability to continue as a going concern, the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, including the proposed Merger with Cullgen, is set forth in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor

Contact:

Chuck

Padala

Managing

Director

LifeSci

Advisors

646-627-8390 chuck@lifesciadvisors.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Pulmatrix earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.